Therapeutic efficacy of combining PEGylated liposomal doxorubicin and radiofrequency (RF) ablation: Comparison between slow-drug-releasing, non-thermosensitive and fast-drug-releasing, thermosensitive nano-liposomes

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Andriyanov, Alexander V ^a   Koren, Erez ^a   Barenholz, Yechezkel ^a   Goldberg, S Nahum ^b,c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME; DELAYED RELEASE FORMULATION; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EFFECTIVENESS; CONTINUOUS DRUG RELEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG LIVER LEVEL; DRUG RELEASE; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FAST DRUG RELEASE; GROWTH RATE; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; MOUSE; NONHUMAN; RADIOFREQUENCY ABLATION; SLOW DRUG RELEASE; SURVIVAL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CATHETER ABLATION; CHEMISTRY; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG SCREENING; MORTALITY; NEOPLASMS; PROCEDURES; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CATHETER ABLATION; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DOXORUBICIN; HUMANS; LIPOSOMES; MICE; NEOPLASMS; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901218029     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092555     Document Type: Article

References (74)

1. Gregoriadis G (1981) Targeting of drugs: implications in medicine. Lancet 2: 241-246.
2. Torchilin VP (2010) Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol: 3-53.
3. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271-284. (Pubitemid 30122932)
4. Schroeder A, Sigal A, Turjeman K, Barenholz Y (2008) Using PEGylated nanoliposomes to target tissue invaded by a foreign body. J Drug Target 16: 591-595.
5. Avnir Y, Turjeman K, Tulchinsky D, Sigal A, Kizelsztein P, et al. (2011) Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids. PLoS One 6: 1-14.
6. Zucker D, Andriyanov AV, Steiner A, Raviv U, Barenholz Y (2012) Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. Journal of controlled release 160: 281-289.
7. Zucker D, Barenholz Y (2010) Optimization of vincristine-topotecan combination-paving the way for improved chemotherapy regimens by nanoliposomes. J Control Release 146: 326-333.
8. Barenholz Y (2012) Doxil(R) - the first FDA-approved nano-drug: lessons learned. J Control Release 160: 117-134.
9. Bandak S, Goren D, Horowitz A, Tzemach D, Gabizon A (1999) Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs 10: 911-920. (Pubitemid 30061363)
10. Lasic DD, Vallner JJ, Working PK (1999) Sterically stabilized liposomes in cancer therapy and gene delivery. Curr Opin Mol Ther 1: 177-185. (Pubitemid 29238422)
11. Barenholz Y (2013) and co-authors; In preparation.
12. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4: 145-160.
13. Schroeder A, Avnir Y, Weisman S, Najajreh Y, Gabizon A, et al. (2007) Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility. Langmuir 23: 4019-4025. (Pubitemid 46581936)
14. Volodkin DV, Skirtach AG, Möhwald H (2009) Near-IR Remote Release from Assemblies of Liposomes and Nanoparticles. Angewandte Chemie International Edition 48: 1807-1809.
15. Barenholz Y, Cevc G (2000) Physical Chemistry of Biological Interfaces. In: Baszkin A, Norde W, editors. New York: Marcel Dekker. 171-241.
16. Moussa M, Goldberg SN, Tasawwar B, Sawant RR, Levchenko T, et al. (2013) Adjuvant Liposomal Doxorubicin Markedly Affects Radiofrequency Ablation-induced Effects on Periablational Microvasculature. Journal of Vascular and Interventional Radiology 24: 1021-1033.
17. Leung SJ, Romanowski M (2012) Light-activated content release from liposomes. Theranostics 2: 1020-1036.
18. Needham D, Park JY, Wright AM, Tong J (2013) Materials characterization of the low temperature sensitive liposome (LTSL): effects of the lipid composition (lysolipid and DSPE-PEG2000) on the thermal transition and release of doxorubicin. Faraday Discuss 161: 515-534; discussion 563-589.
19. Garbuzenko O, Barenholz Y, Priev A (2005) Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids 135: 117-129. (Pubitemid 40744733)
20. Mouritsen OG, Jorgensen K (1994) Dynamical order and disorder in lipid bilayers. Chem Phys Lipids 73: 3-25. (Pubitemid 24299185)
21. Barenholz Y (2004) Sphingomyelin and cholesterol: from membrane biophysics and rafts to potential medical applications. Subcellular Biochemistry 37: 167-216.
22. Gabizon A, Martin F (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54 Suppl 4: 15-21. (Pubitemid 27487791)
23. Lasic DD, Frederik PM, Stuart MC, Barenholz Y, McIntosh TJ (1992) Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett 312: 255-258.
24. Needham D, Dewhirst MW (2001) The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 53: 285-305. (Pubitemid 34024911)
25. Needham D, Anyarambhatla G, Kong G, Dewhirst MW (2000) A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 60: 1197-1201. (Pubitemid 30151982)
26. Celsion (2012) Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC). Available: http://clinical-trials.findthedata.org/l/93100/Phase-3-Study-of-ThermoDox-With- Radiofrequency-Ablation-RFA-in-Treatment-of-Hepatocellular-Carcinoma-HCC.
27. Poon RT, Borys N (2011) Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future Oncol 7: 937-945.
28. Mills JK, Needham D (2005) Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochim Biophys Acta 1716: 77-96. (Pubitemid 41532286)
29. Poon RT, Borys N (2009) Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother 10: 333-343.
30. Banno B, Ickenstein LM, Chiu GN, Bally MB, Thewalt J, et al. (2010) The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo. J Pharm Sci 99: 2295-2308.
31. Al-Jamal WT, Al-Ahmady ZS, Kostarelos K (2012) Pharmacokinetics & tissue distribution of temperature-sensitive liposomal doxorubicin in tumor-bearing mice triggered with mild hyperthermia. Biomaterials 33: 4608-4617.
32. Skeel RT (2011) Biologic and Pharmacologic Basis of Cancer Chemotherapy, in: Handbook of cancer chemotherapy; Skeel RT, Khleif SN, editors. Boston, MA: Wolters Kluwer Health.
33. Abouzeid AH, Torchilin VP (2013) The role of cell cycle in the efficiency and activity of cancer nanomedicines. Expert Opin Drug Deliv 10: 775-786.
34. Landon CD, Park JY, Needham D, Dewhirst MW (2011) Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer. The Open Nanomedicine Journal 3: 38-64.
35. Tagami T, Ernsting MJ, Li SD (2011) Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system. J Control Release 154: 290-297.
36. Gasselhuber A, Dreher MR, Negussie A, Wood BJ, Rattay F, et al. (2010) Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation. Int J Hyperthermia 26: 499-513.
37. Monsky WL, Kruskal JB, Lukyanov AN, Girnun GD, Ahmed M, et al. (2002) Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model. Radiology 224: 823-829. (Pubitemid 34919820)
38. Ahmed M, Monsky WE, Girnun G, Lukyanov A, D'Ippolito G, et al. (2003) Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res 63: 6327-6333. (Pubitemid 37255180)
39. Gazelle GS, Goldberg SN, Solbiati L, Livraghi T (2000) Tumor ablation with radio-frequency energy. Radiology 217: 633-646.
40. Dupuy DE, Goldberg SN (2001) Image-guided radiofrequency tumor ablation: challenges and opportunities-part II. J Vasc Interv Radiol 12: 1135-1148. (Pubitemid 32983350)
41. Solazzo SA, Ahmed M, Schor-Bardach R, Yang W, Girnun GD, et al. (2010) Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology 255: 62-74.
42. Jacobsen PF, Jenkyn DJ, Papadimitriou JM (1985) Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice. J Neuropathol Exp Neurol 44: 472-485. (Pubitemid 15230875)
43. Mahoney DH Jr, Steuber CP, Sandbach JF, Fernbach DJ (1986) Extraneural metastases from medulloblastoma: long-term survival after sequentially scheduled chemotherapy and radiotherapy. Med Pediatr Oncol 14: 329-331. (Pubitemid 17217052)
44. Hacker S, Karl S, Mader I, Cristofanon S, Schweitzer T, et al. (2011) Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. Oncogene 30: 2275-2281.
45. Barenholz Y, Amsalem S (1993) Liposome Technology (Gregoriadis, G., Ed). CRC Press, Boca Raton, FL. 527-616.
46. Haran G, Cohen R, Bar LK, Barenholz Y (1993) Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151: 201-215. (Pubitemid 23283973)
47. Storm G, van Bloois L, Brouwer M, Crommelin DJ (1985) The interaction of cytostatic drugs with adsorbents in aqueous media. The potential implications for liposome preparation. Biochim Biophys Acta 818: 343-351. (Pubitemid 15019093)
48. Amselem S, Gabizon A, Barenholz Y (1990) Optimization and upscaling of doxorubicin-containing liposomes for clinical use. J Pharm Sci 79: 1045-1052.
49. Garbuzenko O, Zalipsky S, Qazen M, Barenholz Y (2005) Electrostatics of PEGylated micelles and liposomes containing charged and neutral lipopolymers. Langmuir 21: 2560-2568. (Pubitemid 40421909)
50. Bartlett GR (1959) Phosphorus assay in column chromatography. J Biol Chem 234: 466-468.
51. Biltonen RL, Lichtenberg D (1993) The Use of Differential Scanning Calorimetry as a Tool to Characterize Liposome Preparations. Chem Phys Lipids 64: 129-142. (Pubitemid 23290870)
52. Goldberg SN, Kruskal JB, Oliver BS, Clouse ME, Gazelle GS (2000) Percutaneous tumor ablation: increased coagulation by combining radiofrequency ablation and ethanol Instillation in a rat breast tumor Model. Radiology 217: 827-831.
53. Moussa M, Goldberg S, Tasawwar B, Sawant R, Levchenko T, et al. (2013) Adjuvant Liposomal Doxorubicin Markedly Affects Radiofrequency Ablation-induced Effects on Periablational Microvasculature. Journal of vascular and interventional radiology: JVIR: 1021-1033.
54. Yang W, Ahmed M, Tasawwar B, Levchenko T, Sawant RR, et al. (2011) Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model. International Journal of Hyperthermia 27: 527-538.
55. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, et al. (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992. (Pubitemid 24085451)
56. Goldberg SN, Kruskal JB, Oliver BS, Clouse ME, Gazelle GS (2000) Percutaneous tumor ablation: increased coagulation by combining radiofrequency ablation and ethanol instillation in a rat breast tumor model. Radiology 217: 827-831.
57. Euhus DM, Hudd C, LaRegina MC, Johnson FE (1986) Tumor measurement in the nude mouse. Journal of Surgical Oncology 31: 229-234. (Pubitemid 16104025)
58. Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemotherapy and Pharmacology 24: 148-154. (Pubitemid 19163397)
59. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170.
60. Cumming G, Fidler F, Vaux DL (2007) Error bars in experimental biology. J Cell Biol 177: 7-11. (Pubitemid 46588396)
61. Mayer LD, Tai LC, Bally MB, Mitilenes GN, Ginsberg RS, et al. (1990) Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1025: 143-151. (Pubitemid 20199621)
62. Swenson CE, Perkins WR, Roberts P, Janoff AS (2001) Liposome technology and the development of Myocet (TM) (liposomal doxorubicin citrate). Breast 10: 1-7.
63. Goldberg SN, Kamel IR, Kruskal JB, Reynolds K, Monsky WL, et al. (2002) Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. American Journal of Roentgenology 179: 93-101. (Pubitemid 34694817)
64. Mouritsen OG, Jørgensen K (1998) A new look at lipid-membrane structure in relation to drug research. Pharmaceutical research 15: 1507-1519. (Pubitemid 28465735)
65. Zhang X, Luckham PF, Hughes AD, Thom S, Xu XY (2013) Towards an understanding of the release behavior of temperature-sensitive liposomes: a possible explanation of the "pseudoequilibrium" release behavior at the phase transition temperature. J Liposome Res: 167-173.
66. Torchilin V (2012) Next Step in Drug Delivery: Getting to Individual Organelles. Drug Deliv Transl Res 2: 415-417.
67. Kale AA, Torchilin VP (2010) Environment-responsive multifunctional liposomes. Methods Mol Biol 605: 213-242.
68. Koren E, Apte A, Jani A, Torchilin VP (2012) Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release 160: 264-273.
69. Ferrandina G, Corrado G, Licameli A, Lorusso D, Fuoco G, et al. (2010) Pegylated liposomal doxorubicin in the management of ovarian cancer. Ther Clin Risk Manag 6: 463-483.
70. Gasselhuber A, Dreher MR, Rattay F, Wood BJ, Haemmerich D (2012) Comparison of conventional chemotherapy, stealth liposomes and temperature-sensitive liposomes in a mathematical model. PLoS One 7: 1-11.
71. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, et al. (1991) Sterically Stabilized Liposomes - Improvements in Pharmacokinetics and Antitumor Therapeutic Efficacy. Proceedings of the National Academy of Sciences of the United States of America 88: 11460-11464. (Pubitemid 21916061)
72. Ku Y, Saitoh M, Iwasaki T, Tominaga M, Maekawa Y, et al. (1993) Intraarterial infusion of high-dose adriamycin for unresectable hepatocellular carcinoma using direct hemoperfusion under hepatic venous isolation. Eur J Surg Oncol 19: 387-392. (Pubitemid 23269064)
73. Lewandowski RJ, Geschwind JF, Liapi E, Salem R (2011) Transcatheter intraarterial therapies: rationale and overview. Radiology 259: 641-657.
74. Ahmed M, Liu Z, Lukyanov AN, Signoretti S, Horkan C, et al. (2005) Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology 235: 469-477. (Pubitemid 40571084)